MacroGenics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello, everyone, and welcome back. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with MacroGenics, a commercial-stage oncology biotech with a broad antibody-based platform. Joining us today is Scott Koenig, CEO of MacroGenics. Thank you and welcome. We always enjoy having you here at our conference, Scott. Before we hop into Q&A, could you perhaps provide a two- to three-minute overview of MacroGenics, your pipeline, and your platform?
It'd be my pleasure. And thanks so much for inviting us to participate in the conference today. So MacroGenics is a company that has been in over 20 years of operation. From our inception, we've been focused on immune-based therapeutics, developing proprietary platforms where we modify the structure of antibodies for various therapeutic purposes. We have three major platform technologies. One around our FC engineering, where we're able to engage immune
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
